NLS Pharmaceutics AG
NLS Pharmaceutics AG
Your view on NLSPW
Overview
What the company does, where it operates, and who runs it.
About NLS Pharmaceutics AG
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Alexander Zwyer
- Headquarters
- The Circle 6, Zurich, CH
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Alexander Zwyer
- Headquarters
- The Circle 6, Zurich, CH
NLS Pharmaceutics AG is a biopharmaceutical firm currently in its clinical development phase, concentrating on identifying and advancing therapeutic interventions for individuals affected by complex and uncommon conditions impacting the central nervous system (CNS). The company's research and development primarily target narcolepsy, idiopathic hypersomnia, and various other infrequent sleep disorders, alongside neurodevelopmental conditions like attention deficit hyperactivity disorder (ADHD). Key product candidates in their pipeline include Quilience, designed to alleviate excessive daytime drowsiness and cataplexy, and Nolazol, which aims to treat ADHD. Additionally, NLS Pharmaceutics is progressing several other compounds: NLS-4, a selective dopamine reuptake inhibitor for rare sleep disorders; NLS-3, a repurposed methylphenidate ester for ADHD treatment; and NLS-8, a melatonin ML1A receptor agonist that has shown promise in improving scopolamine-induced amnesia. Their portfolio also features NLS-11, a norepinephrine and dopamine reuptake inhibitor with muscarinic M1, M2, M3 receptor antagonist properties, and NLS-12, another norepinephrine and dopamine reuptake inhibitor that functions as a muscarinic M4 receptor antagonist. Established in 2015, NLS Pharmaceutics AG is headquartered in Zurich, Switzerland.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks the stock is worth vs. the current price.
FRC's fair value estimate for NLS Pharmaceutics AG, and the rating behind it. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for NLS Pharmaceutics AG. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for NLS Pharmaceutics AG. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for NLS Pharmaceutics AG. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for NLS Pharmaceutics AG. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
NLS Pharmaceutics AG valued side by side against its closest peers. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold NLS Pharmaceutics AG, and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by NLS Pharmaceutics AG executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming NLS Pharmaceutics AG. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming NLS Pharmaceutics AG. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
Latest headlines and company announcements for NLS Pharmaceutics AG. Press releases and market coverage, newest first.